Subthalamic hGAD65 Gene Therapy and Striatum TH Gene Transfer in a Parkinson’s Disease Rat Model

Table 2

Concentration of DA in the striatum (nmol/L, 𝑛=6).

Fibroblasts (TH)

rAAV-hGAD65

Combination

Fibroblasts

rAAV2 vector

PBS

Concentration

Percent of control

Concentration

Percent of control

Concentration

Percent of; control

Concentration

Percent of control

Concentration

Percent of control

Concentration

Percent of; control

4 W

5.58±0.65 **

10.54 ± 1.23%

1.22±0.23^**##

2.30±0.43%

6.41±0.54^##

12.10 ± 0.97%

1.24±0.25^**##

2.32±0.27%

1.30±0.26^**##

2.41±0.51%

1.31±0.29^**##

2.46±0.71%

8 W

4.33±0.74 **

8.17±1.41%

1.04±0.16^**##

1.97±0.30%

4.80±0.41^##

9.07±0.78%

1.03±0.31^**##

1.96±0.34%

1.09±0.26^**##

2.02±0.47%

1.10±0.21^**##

2.11±0.54%

16 W

3.77±0.37 **

7.11±0.70%

0.59±0.15^**##

1.10±0.27%

4.20±0.41^##

7.93±0.78%

0.61±0.15^**##

1.11±0.30%

0.65±0.21^**##

1.13±0.44%

0.67±0.23^**##

1.16±0.28%

Statistical significance (**, ^##) in the concentrations of DA in the striatum between the rAAV2-hGAD65-treated group and the TH-treated group or the combination-treated group, at 4, 8, and 16 weeks after treatment (𝑃<0.001, 𝑛=6). The DA level of rAAV2-hGAD65 group was similar to that of three control groups (fibroblasts, rAAV2 vector, and PBS groups at 4, 8, and 16 week after treatment, respectively (𝑃>0.05, 𝑛=6). Fibroblasts (TH), fibroblasts transferred by rAd-TH; rAAV2-hGAD65, recombinant adeno-associated virus particles, containing human glutamic acid decarboxylase 2 gene; combination, rAAV2-hGAD65 + fibroblasts (TH), fibroblasts, primary cultrued fibroblasts, rAAV2 vector, recombinant AAV2 particles, PBS, pH = 7.2, 0.1 M.